ND AML group:CRc: 100%MRD MFC 10-4: 78%FLT3 PCR MRD 10-2 - 10-3: 90%Median OS: NRR/R AML group:CRc: 68%MRD MFC 10-4: 29%FLT3 PCR MRD 10-2 - 10-3: 36%(gilteritinib-exposed R/R cohort)Median OS: 7.1 mts1-year OS: 22%. Here, FLT3 is linked to acute myeloid leukemia.